Neurology Reviews® and Greenwich Biosciences Release the

Cannabis and CBD Study

View PDF

The study, based on a survey of frontline clinicians, shows that most physicians are self-educating on the topic of cannabis/cannabinoids or receiving no training at all  

Parsippany, NJ – Neurology Reviews and Greenwich Biosciences announce the release of the Cannabis and CBD Study, which was undertaken to ascertain what physicians know about current and potential cannabis-related therapies and the current laws surrounding use of cannabis for medical purposes and testing. The study uncovers a lack of organized training, which has led to knowledge gaps about cannabis and cannabinoids like cannabidiol (CBD) and tetrahydrocannabinol (THC), the endocannabinoid system, and regulatory requirements.

Greenwich Biosciences and Neurology Reviews were instrumental in conducting the knowledge gap survey that underscores the vital responsibility this publication and larger networking has in disseminating clinically sound evidence about cannabis and cannabinoids to practitioners. The survey highlighted that most physicians are self-educating on the topic of cannabis and cannabinoids rather than receiving formal training.

It revealed that nearly two-thirds of physicians self-educate on the topic of cannabis and cannabinoids. Remarkably, 21% say they are not using any form of training to better understand this important topic. Moreover, four in every ten physicians report receiving no training about the human endocannabinoid system.

This lack of organized training appears to be contributing to a knowledge gap about cannabis, CBD, THC, and the endocannabinoid system. For example, half of the respondents did not know whether or not 0.3% THC has been clinically proven safe (it hasn’t). There are also misunderstandings about the mechanisms of THC and CBD, classes of cannabinoids, and the cannabis plant itself. Alarmingly, nearly 1 in 6 physicians surveyed were unaware that testing standards of state-regulated cannabis products are not controlled by the FDA.

To learn more about the cannabis and CBD initiatives of Neurology Reviews and Greenwich Biosciences, contact Elizabeth Katz at 973-224-7951 or [email protected]. Details and information on all FMC/MDedge digital brands, print publications, and custom programs are available at http://www.frontlinemedcom.com; visit weekly for the latest innovative programs and multimedia initiatives.

About Neurology Reviews and MDedge Neurology

Launched in 1993, Neurology Reviews® is the first and original news source in neurology. Neurology Reviews® has a 27-year history of providing independent, unbiased news to neurologists and clinicians interested in the neurosciences. Neurology Reviews® covers medical conferences and clinical research findings, as well as specialty trends, expert opinions, and the breadth of influences affecting the practice of neurology. Experienced medical journalists deliver timely, relevant, and insightful news affecting the practice of neurology and all its subspecialties. In addition to the monthly print issue reaching nearly 25,000 neurologists and clinicians interested in neuroscience, the Neurology Reviews® website www.mdedge.com/neurology, part of the MDedge® web portal, features online ahead of print conference reporting, audio and video interviews, disease-specific microsites, self-assessment quizzes, supplements, sponsored educational programs, a calendar of relevant medical meetings, and a career center listing job openings around the country. Neurology Reviews® provides its content in print, through an App, on a mobile-friendly website, in digital editions, and through targeted e-blasts.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company also has approval in Europe for these indications. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions including Tuberous Sclerosis Complex (TSC) and Rett syndrome. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.

 

About Frontline Medical Communications

Frontline Medical Communications Inc. is one of the healthcare industry’s largest medical communications companies and a leader in digital, print, and live events. The Company leads in HCP-level targeting and is ranked 1st in combined web and print engagements. With MDedge®, our state-of-the-art integrated web portal, and audited email database, FMC meets the marketing challenges of our clients with superior reach, optimal sponsorship opportunities, and flexible advertising programs. We reach 1.2 million+ physicians, NPs, PAs, HCPs, and key healthcare decision makers through more than 30 media brands serving 20 distinct markets, who access our content through an array of digital, print, and face to face channels and social media platforms. FMC delivers award-winning, indexed, clinical reviews; practice and policy information; and medical news daily from on-site reporting at major medical meetings, many in collaboration with notable societies, medical associations, and opinion leaders. FMC produces live events, digital click-for-credit, and CME in affiliation with Global Academy for Medical Education, LLC (globalacademycme.com) and Hemedicus (hemedicus.com).

Visit www.frontlinemedcom.com | Twitter | Facebook | LinkedIn.

Contact:
Elizabeth Katz, Publisher, [email protected], 973.224.7951

Frontline Medical Communications
Corporate office: 7 Century Drive, Suite 302
Parsippany, NJ 07054-4609 | Main: 973.206.3434 | Fax: 973.206.9378
www.frontlinemedcom.com| www.frontlinerates.com | General Email: [email protected]